ELIAS ANIMAL HEALTH

www.eliasanimalhealth.com

# GROUNDBREAKING NEW IMMUNOTHERAPY FOR CANINE OSTEOSARCOMA

ELIAS Cancer Immunotherapy (ECI®) is the only combination adoptive T cell therapy available in veterinary medicine

## WHAT IS IT?

ECI® is a vaccine primed form of adoptive T cell therapy, which has been developed for the treatment of canine osteosarcoma and, potentially, other types of canine cancers. Instead of genetically manipulating T cells or harvesting these cells directly from tumor tissue, ECI® uses autologous attenuated cancer cell vaccines manufactured from surgically removed host cancer tissue. These autologous vaccines are used to condition host T cells to the cancer antigens. The vaccine-primed mononuclear cells are later harvested via apheresis, and expanded and activated *ex vivo* prior to manufacture a killer T cell infusion that targets cancer cells and causes apoptosis.

## ECI® STUDY RESULTS

| **Study** | **ECI-OSA-01** (completed) *n=14* | **ECI-OSA-04** (ongoing) *n=100* |
|---|---|---|
| **Safety** | Reported AEs were generally mild to moderate:<br>• Vaccine: 14 reports of Grade 1 injection site reactions; one report of Grade 1 vomiting<br>• T cell infusion: 7 reports of Grades 1-2, and one manageable Grade 3 pyrexia (fever)<br><br>Treatment found to be safe and tolerable | • Multi-center, randomized trial<br>• Control group is carboplatin<br>• Results expected in late 2022 |
| **Efficacy** | Outcomes observed:<br>• CR and PR with remission of metastatic disease<br>• Slow DP progression in some patients<br>  ◦ Median Survival Time = 415 days<br>  ◦ 5 dogs alive 719-946 days at study end<br>  ◦ 4 of those 5 with no evidence of disease | |

ELIAS ANIMAL HEALTH



# How will you make a difference for your canine patients?

Ideal candidates for ECI® are dogs with newly diagnosed appendicular osteosarcoma (limb intact) that have no signs of metastatic disease at diagnosis

## RESULTS OBSERVED IN HUMANS

The protocol for canine osteosarcoma is adapted from the human version of this immunotherapy that was used in Phase 1/2 clinical trials. It has demonstrated efficacy in human Phase 2 trials against stage IV renal carcinoma and recurrent malignant melanoma.

### Exciting Progress

In April 2020, this immunotherapy was given FastTrack designation by the FDA for development in humans. ELIAS' canine osteosarcoma data was a key component in achieving this milestone.

## FIND OUT HOW TO BRING ECI® TO YOUR PATIENTS


913-492-2221

info@eliasah.com

www.eliasanimalhealth.com


## ECI® IS AVAILABLE FOR CANINE OSTEOSARCOMA PATIENTS NOW

ECI® is authorized by the USDA for sale to licensed veterinarians prior to full approval.

- Administered to more than 200 dogs through clinical trials or commercial use
- Available in 23 states and expanding; authorized in all 50 states and District of Columbia
- 17 apheresis centers participating (and expanding)

Contact ELIAS Animal Health to learn how your hospital can offer ECI® and bring new hope to your patients and their families.

ECI® is an experimental autologous prescription product available for sale to veterinarians under 9 CFR 103.3. Safety and efficacy have not been established.



ACVIM 06-2022